[{"id":"5d9596a1-d384-4d3e-99e8-4001de1a4302","acronym":"EVOLVE CLL/SLL","url":"https://clinicaltrials.gov/study/NCT04269902","created_at":"2021-01-18T20:44:42.322Z","updated_at":"2025-02-25T12:27:29.630Z","phase":"Phase 3","brief_title":"Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study","source_id_and_acronym":"NCT04269902 - EVOLVE CLL/SLL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 03/02/2021","start_date":" 03/02/2021","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-24"},{"id":"be1f4791-7f5f-42b3-86ee-a6bfee99acee","acronym":"ASSURE","url":"https://clinicaltrials.gov/study/NCT04008706","created_at":"2021-01-18T19:41:49.844Z","updated_at":"2025-02-25T14:07:28.508Z","phase":"Phase 3","brief_title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","source_id_and_acronym":"NCT04008706 - ASSURE","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • CD20 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • IGH mutation","tags":["TP53 • CD20 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-17"},{"id":"814f07a4-6ae3-424e-b8de-ef7b7143e4c7","acronym":"BELLWAVE-010","url":"https://clinicaltrials.gov/study/NCT05947851","created_at":"2023-07-17T14:08:45.600Z","updated_at":"2025-02-25T15:28:11.395Z","phase":"Phase 3","brief_title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","source_id_and_acronym":"NCT05947851 - BELLWAVE-010","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • BTK • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • BTK • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 08/08/2023","start_date":" 08/08/2023","primary_txt":" Primary completion: 06/27/2033","primary_completion_date":" 06/27/2033","study_txt":" Completion: 06/27/2033","study_completion_date":" 06/27/2033","last_update_posted":"2025-02-11"},{"id":"63e0d60a-e16f-4451-bd50-7c30a33e2a8d","acronym":"BELLWAVE-008","url":"https://clinicaltrials.gov/study/NCT05624554","created_at":"2022-11-22T15:58:55.794Z","updated_at":"2024-07-02T16:34:25.934Z","phase":"Phase 3","brief_title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","source_id_and_acronym":"NCT05624554 - BELLWAVE-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • Truxima (rituximab-abbs) • fludarabine IV • nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 05/19/2027","primary_completion_date":" 05/19/2027","study_txt":" Completion: 03/17/2031","study_completion_date":" 03/17/2031","last_update_posted":"2024-06-14"},{"id":"cbf25b80-812c-4077-9111-bd170e1a9071","acronym":"","url":"https://clinicaltrials.gov/study/NCT03219450","created_at":"2021-01-18T15:53:18.906Z","updated_at":"2025-02-25T16:06:35.068Z","phase":"Phase 1","brief_title":"A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.","source_id_and_acronym":"NCT03219450","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IGH","pipe":" | ","alterations":" IGH mutation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Neo Vax (NEO-PV-01) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-04-23"},{"id":"31c8b0b8-4268-4696-a0fc-94d1c47df131","acronym":"","url":"https://clinicaltrials.gov/study/NCT05168930","created_at":"2021-12-23T16:53:47.789Z","updated_at":"2024-07-02T16:35:24.052Z","phase":"Phase 2","brief_title":"Zanubrutinib and Venetoclax in CLL (ZANU-VEN)","source_id_and_acronym":"NCT05168930","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 10/28/2025","primary_completion_date":" 10/28/2025","study_txt":" Completion: 10/28/2028","study_completion_date":" 10/28/2028","last_update_posted":"2024-01-09"},{"id":"ac53ce88-6dcf-4d5a-8b35-500b4f2a432f","acronym":"VeRitAs","url":"https://clinicaltrials.gov/study/NCT03455517","created_at":"2021-01-18T17:02:15.141Z","updated_at":"2024-07-02T16:35:28.111Z","phase":"Phase 2","brief_title":"Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT03455517 - VeRitAs","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab)"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 09/05/2021","primary_completion_date":" 09/05/2021","study_txt":" Completion: 05/11/2023","study_completion_date":" 05/11/2023","last_update_posted":"2023-11-24"},{"id":"5ffbbc17-57b3-456e-842a-ec4beb3e26b9","acronym":"STAIR","url":"https://clinicaltrials.gov/study/NCT04963946","created_at":"2021-07-15T13:06:20.234Z","updated_at":"2024-07-02T16:35:47.235Z","phase":"Phase 2","brief_title":"STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT04963946 - STAIR","lead_sponsor":"French Innovative Leukemia Organisation","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 04/15/2024","primary_completion_date":" 04/15/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-05-24"},{"id":"43cc2176-b27f-4bca-b397-b12e19417b2d","acronym":"iLLUMINATE ","url":"https://clinicaltrials.gov/study/NCT02264574","created_at":"2021-01-17T17:35:09.358Z","updated_at":"2024-07-02T16:36:40.852Z","phase":"Phase 3","brief_title":"A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT02264574 - iLLUMINATE ","lead_sponsor":"Pharmacyclics LLC.","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • TP53 mutation + Chr del(17p) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Leukeran (chlorambucil)"],"overall_status":"Completed","enrollment":" Enrollment 229","initiation":"Initiation: 10/06/2014","start_date":" 10/06/2014","primary_txt":" Primary completion: 03/26/2018","primary_completion_date":" 03/26/2018","study_txt":" Completion: 09/03/2019","study_completion_date":" 09/03/2019","last_update_posted":"2020-09-21"},{"id":"4807b783-568e-4986-96b0-9f77b955c9d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01460238","created_at":"2021-01-18T06:04:15.647Z","updated_at":"2024-07-02T16:37:01.191Z","phase":"","brief_title":"Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01460238","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" IGH","pipe":" | ","alterations":" IGH mutation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH mutation"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2019-03-28"},{"id":"67592ff1-2eef-41c1-bb33-147db74c0221","acronym":"","url":"https://clinicaltrials.gov/study/NCT01003821","created_at":"2021-01-18T03:55:27.706Z","updated_at":"2025-02-25T14:31:25.818Z","phase":"","brief_title":"Lenalidomide as a Chemopreventive Agent for High-Risk Early Stage B-cell Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT01003821","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IGH","pipe":" | ","alterations":" IGH mutation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":"","study_completion_date":"","last_update_posted":"2016-06-30"}]